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Abstract
Background: In children with eosinophilic esophagitis (EoE) foods are the most common 
disease triggers, but environmental allergens are also suspected culprits.
Objective: To determine the effects of environmental allergen sensitization on response to 
treatment in children with EoE in the southeastern United States.
Methods: Patients 2 to 18 years old who were referred to the Arkansas Children’s Hospital 
Eosinophilic Gastrointestinal Disorders Clinic from January 2012 to January 2016 were enrolled 
in a prospective, longitudinal cohort study with collection of demographics, clinical symptoms, 
medical history, allergy sensitization profiles, and response to treatment over time. Comparisons 
were made between complete responders (peak esophageal eosinophil count <15 per high-power 
field [HPF]) and nonresponders (>25 eosinophils per HPF) after treatment with diet elimination 
alone, swallowed corticosteroids alone, or diet elimination and swallowed corticosteroids. 
Sensitization patterns to environmental allergens found in the southeastern United States were 
analyzed for the effect on treatment response.
Reprints: Robert D. Pesek, MD, Division of Allergy/Immunology, Arkansas Children’s Hospital, 13 Children’s Way, Slot 512-13, 
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Results: A total of 223 individuals were enrolled. Of these, 182 had environmental allergy 
profiling and at least one endoscopy while receiving proton pump inhibitor (PPI) therapy. Twenty-
nine individuals had PPI-responsive EoE and were excluded from further analysis, leaving 123 
individuals with none-PPI-responsive EoE who were further analyzed; 72 (58.5%) were complete 
responders and 33 (26.8%) were nonresponders. Seventeen individuals (13.8%) were partial 
responders (≥ 1 but ≤ 25 eosinophils per HPF) and excluded from further analysis. Nonresponders 
were more likely to be sensitized to perennial allergens (P = .02). There was no significant 
difference in response based on seasonal allergen sensitization. Individuals with mold or 
cockroach sensitization were more likely to fail combination diet and swallowed corticosteroid 
treatment (P = .02 and P = .002).
Conclusion: Perennial allergen and mold sensitization may lead to nonresponse to EoE 
treatment in some patients. Additional studies are needed to further understand the effect of 
environmental allergens on EoE.
Trial Registration: http://ClinicalTrials.gov identifier: NCT01779154.
Introduction
Eosinophilic esophagitis (EoE) is an increasing clinical problem. Estimates of prevalence in 
the United States have increased from 2.3 per 100,000 population in 1976 to 25.9 per 
100,000 population in 2015, with even higher rates reported in some populations.1–4 
Characterized by eosinophilic inflammation of the esophagus, affected patients may 
experience a variety of clinical symptoms that lead to increased health care use and 
decreased quality of life.5 Diagnostic options are limited to repetitive endoscopy, whereas 
treatment is centered on use of swallowed corticosteroids or diet restrictions. Although food 
remains the most common trigger,6,7 the role of aeroallergens in the development of EoE has 
also been questioned. Several studies have found changing clinical symptoms during peak 
pollen seasons, especially in those with concomitant allergic rhinitis.8–10 The frequency of 
diagnosis also appears to increase during pollen seasons, with a lower frequency found in 
winter.11–14 However, other studies have found no clear link among aeroallergen 
sensitization, symptom onset, and seasonal diagnosis of EoE.15–18
Most EoE studies have been completed in urban populations. It is unclear whether there are 
differences in disease presentation and response to management in rural or other nonurban 
populations.16,18–20 As such, characterization of different patient populations is important to 
obtain a clearer understanding of the disease process and to optimize management strategies. 
In 2015, 42% of Arkansas’ population lived in nonurban areas vs 15% for the US population 
as a whole. This nonurban population has not been described compared with those living in 
other environments.21 The purpose of this study was to determine the effects of seasonal and 
perennial allergen sensitization on the response to treatment in a pediatric population with 
EoE living in the southeastern region of the United States.
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Methods
Patient Inclusion
Patients 2 to 18 years of age who were referred to the Arkansas Children’s Hospital 
multispecialty Eosinophilic Gastrointestinal Disorders Clinic from January 2012 to January 
2016 were considered for enrollment. Patients were required to have had at least one 
esophageal endoscopy with findings of 15 eosinophils per high-power field (HPF) or more at 
40× magnification on at least one esophageal biopsy specimen as reviewed by a board-
certified pathologist (R.A.L.). Patients were then consented and enrolled in a prospective, 
longitudinal cohort with collection of data, including demographics, clinical symptoms, 
medical, family, and diet history, allergy profiles, and response to treatment over time. The 
study was approved by the University of Arkansas for Medical Sciences Institutional Review 
Board. Written consent was obtained from each study participant.
Allergy Profiling
Environmental allergen sensitization was determined through use of skin prick testing (SPT) 
and/or serum specific IgE testing (ImmunoCAP, Phadia AB, Uppsala, Sweden). SPT was 
performed using the Greer Pick Single Site Allergy Skin Test System (Greer Labs, Lenoir, 
North Carolina) with histamine and saline controls. Testing to perennial allergens included 
dust mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae), cat hair (Felis 
catus domesticus), dog epithelia (Canis species), cockroach (Periplaneta americana), and 
mold (Aspergillus, Alternaria, Cladosporium, and Curvularia). Seasonal allergens included 
trees (elm, white ash, eastern oak, hickory/pecan, black walnut, birch, mountain cedar, and 
cottonwood), grasses (Bermuda, Bahia, fescue, Johnson, and timothy), and weeds (ragweed, 
pigweed, dock/sorrel, marsh elder, plantain, and hemp) found throughout the southeast 
region of the United States. Individual test results were considered positive if the individuals 
had a SPT wheal size of 3 mm or larger than the negative control and/or a serum specific IgE 
level of 0.35 kU/L or higher. Allergy testing was performed at the initial EoE visit to the 
standard panel of environmental allergens in all patients unless declined by the patient or 
family. Previous allergy testing completed during the 2 years before visit or enrollment was 
also accepted. For most patients, allergy testing was performed before the initiation of EoE 
treatment. Allergy testing performed after initiation of EoE treatment was also accepted. 
Responses to management were compared between patients with seasonal, perennial, and/or 
mold sensitization and those with no sensitization.
Response to Treatment
Response to treatment, including response to proton pump inhibitors (PPI), dietary 
manipulation, and/or use of swallowed corticosteroids, was assessed. All patients were 
assigned to at least 8 weeks of PPI therapy with follow-up endoscopy to assess PPI 
responsiveness. Dosing of PPI was based on physician preference. For those in whom PPI 
treatment failed, management decisions were based on physician and parental preference 
using diet elimination alone, swallowed corticosteroids alone, or a combination of both diet 
elimination and swallowed corticosteroids. If diet manipulation was chosen, the patient was 
placed on allergenspecific elimination (single allergen elimination or combination allergen 
elimination based on allergy testing and clinical history), 6-food elimination (milk, egg, soy, 
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wheat, peanut or tree nuts, fish or shellfish), or elemental diet using an elemental formula 
alone. Patients then received one-on-one dietary counseling provided by a trained dietician. 
If swallowed corticosteroids were choses, the patients were given budesonide (dosing range, 
0.25–1 mg twice daily) or fluticasone propionate (220–880 μg twice daily). If budesonide 
was used, patients were instructed to mix each 2-mL respule with 4 packets of a sugar 
substitute (Splenda). If fluticasone propionate was chosen, patients were instructed to spray 
the inhaler directly into the mouth and swallow. Patients were also instructed to avoid eating 
or drinking for 30 minutes after taking the medication.
Patients continued to receive treatment for at least 10 to 12 weeks before additional 
endoscopy was performed. Patients were considered complete responders if the peak 
esophageal eosinophil count was less than 15 eosinophils per HPF and nonresponders if the 
peak esophageal eosinophil count was greater than 25 eosinophils per HPF. Patients with 
peak eosinophil counts greater than 15 eosinophils per HPF but less than 25 eosinophils per 
HPF were considered partial responders but were excluded from further analysis. Symptom 
improvement was not used as a measure of response to treatment.
Statistical Analysis
All demographics and clinical outcomes were summarized using mean (SD) for continuous 
variables and frequency (percentage) for categorical variables. Categorical variables in 2 
independent groups were compared using a Fisher exact test. Continuous variables in 2 
independent groups were compared using the Wilcoxon rank-sum test. Paired categorical 
outcomes with more than 2 categories were compared using the Bowker test of symmetry. 
Effects for dichotomous outcomes were summarized using odds ratios (ORs) and 95% 
confidence intervals (CIs). All tests conducted were 2-sided, assuming a significance level of 
5%. All statistical analyses were performed using the software R, version 3.0.2. Descriptive 
tables were generated using the Regression Modeling Strategies package.
Results
Study Population
A total of 223 patients were enrolled in the study (Fig 1). Of these, 182 patients had allergy 
profiling to food and environmental allergens and at least one endoscopy while receiving PPI 
therapy. Commonly used PPIs included omeprazole (dose range, 8–40 mg; median, 20 mg), 
lansoprazole (dose range, 10–40 mg; median, 20 mg), and esomeprazole (dose range, 20–40 
mg; median, 40 mg). One patient was excluded from further analysis because there were no 
results available from the follow-up endoscopy and no further endoscopies were performed. 
Twenty-nine patients (15.9%) were considered to have PPI-responsive EoE vs 
gastroesophageal reflux and were also excluded from further analysis. Of the 152 patients 
with none–PPI-responsive EoE, 29 did not have a follow-up endoscopy and were excluded 
from further analysis. A total of 123 patients with none–PPI-responsive EoE had at least one 
follow-up endoscopy and were analyzed for demographics, medical history, clinical 
symptoms, allergen sensitization, and response to management.
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Demographic and Clinical Symptoms
The mean (SD) age at diagnosis was 7.6 (4.88) years with 69% male patients, 86.1% white 
patients, and 9% African American patients (Table 1). Predominant insurance types included 
both Medicaid (44.7%) and private (38.2%), and 41% of patients lived in nonurban counties 
(<65,000 residents). Patients underwent a mean of 3 endoscopies.3,5 Patients were more 
likely to have their conditions diagnosed during the months of July and August and least 
likely to have their conditions diagnosed during September, October, and November, 
although this finding was not statistically significant (Fig 2). Patients had a high incidence of 
atopic disorders (73.2%), including allergic rhinitis (52.8%), asthma (43.1%), food allergy 
(36.6%), and atopic dermatitis (26.8%). More than 40% of patients had a history of 
gastroesophageal reflux. Less than 1% of patients had a prior diagnosis of celiac disease. 
Heartburn or food regurgitation (71.2%), nausea or vomiting (67.3%), abdominal 
pain(55.8%), and dysphagia (50%) were the most common reported symptoms in all age 
groups. Although the occurrence of dysphagia was similar across age groups, food 
impaction (overall, 11.8%) increased with age and occurred most commonly in patients who 
were 12 years or older (40%).
Allergen Profiles
Environmental allergen profiling was completed in a total of 123 patients as previously 
described. Approximately 50% of patients were sensitized to seasonal and perennial 
allergens. Trees were the most common seasonal allergen (44.7%) followed by grasses 
(42.2%), and weeds (39.8%) (Table 2). Dust mites were the most common sensitized 
perennial allergen (34.1%) followed by cat (29.3%) and dog (17.9%) dander. Nearly 30% of 
patients were sensitized to molds. Sensitization to seasonal and perennial allergens increased 
with age, occurring in 43.5% (seasonal) and 50% (perennial) of patients 5 years or younger 
and 69% (seasonal) and 76% (perennial) patients 12 years or older. A similar pattern was 
seen with mold sensitization.
Response to Management
Response to management was assessed in 123 patients with none–PPI-responsive EoE. Of 
those, 72 (58.5%) were complete responders (peak eosinophil count <15 eosinophils per 
HPF), and 33 (26.8%) were nonresponders (peak eosinophil count >25 per HPF). Seventeen 
patients (13.8%) were partial responders (peak eosinophil count ≥15 but ≤25 eosinophils per 
HPF). For all responder groups, there was a decrease in mean (SD) peak eosinophil count 
during the study period: complete responders, 56.2 (39.7) to 2.3 (3.0) eosinophils per HPF 
(92.5% reduction); partial responders, 57.2 (24.7) to 20.1 (3.7) eosinophils per HPF (57.3% 
reduction); and nonresponders, 81.2 (25.2) to 59.4 (24.4) eosinophils per HPF (17.1% 
reduction). In complete responders, 32 patients (44.4%) were managed with diet elimination 
alone, 21 patients (29.2%) with swallowed corticosteroids alone, and 18 patients (25%) with 
both diet elimination and swallowed corticosteroids. One complete responder did not 
implement any management but had clearance of esophageal eosinophils on subsequent 
endoscopy. In nonresponders, 19 patients (57.6%) were managed with diet elimination 
alone, 2 patients (6.1%) with swallowed corticosteroids alone, and 12 patients (36.3%) with 
both diet elimination and swallowed corticosteroids. One nonresponder did not implement 
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any management during the study period and was excluded from analysis. There were no 
significant differences between complete and nonresponders in regard to sex, race, insurance 
type, or county of residence (urban vs nonurban). The most commonly used diet across 
responder groups was allergen-specific food elimination followed by 6-food elimination 
(Table 3). Budesonide was the most commonly used swallowed corticosteroid (daily dosing 
range, 0.5–2 mg; mean, 1 mg) followed by fluticasone propionate (daily dosing range, 220–
1760 μg; mean, 880 μg). When comparing management by age group, children 6 to 11 years 
old and 12 years or older were more likely to be treated with swallowed corticosteroids or 
corticosteroids plus diet elimination, but this difference was not statistically significant (P = .
051).
Effect of Allergen Sensitization on Response to Management
Patients were compared by management response status (complete responders vs 
nonresponders) and allergy testing results (positive vs negative SPT or IgE test results) to 
assess the effects of perennial, mold, and seasonal allergen sensitization on treatment 
response. When comparing complete responders and nonresponders, nonresponders were 
more likely to be sensitized to perennial allergens (P = .02). Patients sensitized to molds 
were also more likely to be nonresponders, although this trend did not reach statistical 
significance. Patients were also analyzed based on the number of allergen groups (ie, dust 
mites, cat, dog, cockroach, molds, trees, grasses, or weeds) that they were sensitized to, but 
no significant differences in response status were found (Table 2). When assessing response 
by age and sensitization pattern, no differences were seen in patients younger than 5 years or 
12 years or older, but patients 6 through 11 years of age were more likely to be 
nonresponders if they had perennial allergen sensitization (P = .02). Overall, no significant 
differences were found in the frequency of nonresponsiveness with increasing age (Table 4). 
There were no significant differences in the response statuses based on age and seasonal 
allergen sensitization.
When individual allergens were analyzed and evaluated for effects on response status, no 
significant difference was found in patients sensitized to dust mites or pet dander. 
Sensitization to cockroach and molds had an effect on response status; in patients who 
underwent combination treatment with both diet elimination and swallowed corticosteroids, 
cockroach or mold sensitization was associated with a higher risk of nonresponse (P = .002 
and P = .02, respectively) (Table 5).
Discussion
In this study, we analyzed the effect of seasonal and perennial allergen sensitization on the 
response to treatment in a pediatric population with EoE living in the southeastern region of 
the United States. Our results indicate that perennial allergen and mold sensitization can 
affect the response to therapy and may increase the risk of nonresponse in certain groups. 
Our population had similar clinical characteristics as reported in other regions, including a 
high rate of atopy and allergen sensitization, suggesting that patients may present similarly 
regardless of geographic location.17,19,22–24 There were also no differences found between 
patients living in rural vs nonrural counties. The most common clinical symptoms included 
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vomiting, abdominal pain, and heart-burn, with older patients having a higher incidence of 
dysphagia and food impaction. Allergen profiling revealed a high rate of both seasonal and 
perennial allergen sensitization, which increased with age.
The role of environmental allergens in EoE has been suggested in multiple studies, with 
evidence of increased diagnosis during peak pollen seasons and worsening clinical 
symptoms.8–13 In the mouse model, delivery of aeroallergens intranasally promotes 
development of eosinophilic inflammation in the esophagus. This effect was not seen if 
aeroallergens were delivered via oral or gastric routes, suggesting that inhalation of 
aeroallergens can promote development of EoE.24 Much of the work thus far has been 
performed in adult populations, which generally show a higher rate of aeroallergen 
sensitization compared with children. Several studies performed in pediatric populations 
have failed to demonstrate an effect of aeroallergens on EoE diagnosis or clinical symptoms.
15–17
Perennial allergens have not been as closely investigated, and because levels may not vary 
during different seasons of the year, their effect on EoE may be more difficult to examine. 
Molds can act as seasonal and perennial allergens, depending on the type of mold and 
environment under consideration. Levels can vary with seasonal changes, but indoor mold 
levels may be more constant throughout the year. Sensitization to molds and perennial 
allergens can be exhibited early in life and is associated with an increased risk of developing 
other atopic disorders, including asthma.25–28 In sensitized patients, these allergens can also 
serve as triggers for exacerbation of existing atopic diseases. Given that many children with 
EoE have coexisting atopic disorders, it would not be surprising to find that these allergens 
may exacerbate EoE.
Although our study did not find a significant effect from seasonal allergens on treatment 
response, perennial allergen sensitization increased the risk of nonresponse to management 
in several groups. This effect was most prevalent in patients 6 through 11 years of age and in 
those sensitized to cockroach and mold who were treated with diet elimination and 
swallowed corticosteroids. This result was not seen in patients 12 years or older, the group 
with the highest environmental allergen sensitization, which may be attributable to the small 
size of the group 12 years or older. These findings suggest that perennial and mold 
sensitization should be determined because there may be an effect on response to treatment, 
at least in some patient groups.
The utility of allergy testing in EoE has been questioned because the underlying mechanism 
does not appear to be IgE mediated.29,30 Although the positive predictive value of allergy 
testing in EoE to foods remains low (44%–47%), skin testing and serum specific IgE testing 
to environmental allergens is higher and more predictive of developing allergic disease in 
children.31–34 Given the correlation shown in our study between sensitization to perennial 
allergens and mold and poor response to management, allergy testing to environmental 
allergens in EoE should be considered. A similar recommendation was made by Olsen et 
al35 in their study of 257 adults with EoE. In their retrospective analysis, adults with 
aeroallergen sensitization were more likely to present with strictures than those who were 
not sensitized. In addition, several case reports have found improvement in the number of 
Pesek et al. Page 7
Ann Allergy Asthma Immunol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
esophageal eosinophils seen in patients with EoE treated for environmental allergens, 
including birch pollen and dust mites, and in each of these cases, the patients had positive 
skin test results to the culprit allergen.36,37
Our study has several limitations. Approximately 18% of patients were excluded from 
treatment response analysis because of a lack of complete SPT or specific IgE testing to 
environmental allergens, which may have decreased the ability to detect differences in 
response to management. In addition, patients were assigned to a treatment plan based on 
practitioner experience and/or patient preference rather than an algorithm-based approach, 
which may have also decreased the potential response rate. PPI therapy may have also been 
discontinued during the study period. If a patient with EoE also had concomitant 
gastroesophageal reflux, discontinuation of the PPI therapy could have led to nonresponse to 
EoE treatment. None of the nonresponders were placed on an elemental diet; thus, it is 
possible that more patients could have achieved at least a partial response if this diet were 
implemented. A formal assessment for adherence with the recommended treatment plan was 
not performed; thus, patient adherence may have also affected the results. In regard to the 
effects of seasonal allergens, endoscopies were not performed based on time or season of the 
year but were performed after management changes. As a result, the effect of seasonal 
allergens on treatment response could have been missed.
Importantly, this is one of the first reports to suggest that sensitization to perennial and mold 
allergens may affect response to therapy in some patients with EoE. Although there were 
several confounding variables, certain patient groups sensitized to mold and/or perennial 
allergens were more likely to be nonresponders. Although use of diet elimination and/or 
swallowed corticosteroids remains the mainstay of treatment in EoE, consideration should 
be given to the pattern of environmental allergen sensitization because it could identify a 
phenotype of patient who may respond differently to management. Such patients may need 
to implement avoidance measures in their home environment to reduce exposure to these 
allergens. There may be benefit from allergen specific immunotherapy, although more work 
is needed to assess the effectiveness of this treatment in EoE. Additional studies are needed 
to determine whether the effects of perennial and mold sensitization on treatment response 
exists in other populations outside the southeast region of the United States.
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Figure 1. 
Study population. Twenty-nine patients had proton pump inhibitor (PPI)–responsive 
eosinophilic esophagitis, and 123 patients with none–PPI-responsive eosinophilic 
esophagitis were further analyzed.
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Figure 2. 
Frequency of eosinophilic esophagitis (EoE) diagnosis based on month of year. Patients 
were more likely to have their conditions diagnosed during the months of July and August 
and least likely to have their conditions diagnosed during September, October, and 
November.
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Table 1
Patient Demographic Characteristicsa
Characteristic Total (N = 123) Complete responders (n = 72) Nonresponders (n = 33) P value
Sex
 Female 38 (30.9) 25 (34.7) 7 (21.2) .18
 Male 85 (69.1) 47 (65.3) 26 (78.8)
Race
 African American 11 (8.9) 7 (9.9) 3 (9.1) .75
 Asian 1 (0.8) 1 (1.4) 0
 White 105 (86.1) 61 (85.9) 28 (84.8)
 Hispanic 1 (0.8) 1 (1.4) 0
 Multiple 4 (3.3) 1 (1.4) 2 (6.1)
Type of insurance
 Medicaid/Medicare 55 (44.7) 33 (45.8) 12 (36.4) .29
 Private 47 (38.2) 9 (12.5) 8 (24.2)
 Multiple 21 (17.1) 30 (41.7) 13 (39.4)
Counties (population)
 Urban (>65,000) 73 (59.3) 43 (59.7) 19 (57.6) .84
 Nonurban (>20,000–64,999) 26 (21.1) 16 (22.2) 9 (27.3)
 Rural (<20,000) 24 (19.5) 13 (18.1) 5 (15.2)
No. of follow-up visits
 0 0 0 0 .12
 1 11 (8.9) 4 (5.6) 5 (15.2)
 2 25 (20.3) 13 (18.1) 9 (27.3)
 ≥3 87 (70.7) 55 (76.4) 19 (57.6)
No. follow-up visits, mean (range) 4 (2–6) 5 (3–8) 3 (2–4) <.001
No. of endoscopies, mean (range) 3.0 (3.0–5.0) 4.5 (3.0–7.0) 3.0 (2.0–3.0) <.001
Age of diagnosis EoE, mean (range), y 8.0 (3.0–11.0) 7.0 (3.0–10.2) 10.0 (4.0–13.0) .18
a
Data are presented as number (percentage) of patients unless otherwise indicated.
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Table 2
Allergen Sensitization Profiles (Positive Skin Prick Test or IgE Test Results)
Variable No. (%) of patients with positive results P value
Total (N = 123) Complete responders (n = 72) Nonresponders (n = 33)
Allergen
 Dust mites 42 (34.1) 24 (34.3) 11 (33.3) >.99
 Cat 36 (29.3) 16 (22.2) 9 (27.3) .62
 Dog 22 (17.9) 11 (15.3) 7 (21.2) .58
 Cockroach 18 (14.6) 6 (8.3) 8 (24.2) .06
 Molds 35 (28.4) 16 (22.2) 14 (42.4) .06
 Trees 55 (44.7) 27 (37.5) 18 (56.2) .20
 Grasses 52 (42.2) 26 (36.1) 18 (56.2) .19
 Weeds 49 (39.8) 24 (33.3) 16 (48.5) .27
Allergen groups
 Perennial NA 33 (45.8) 24 (72.7) .02
 Seasonal NA 32 (47.8) 20 (60.6) .29
 Molds NA 16 (22.2) 14 (42.4) .06
No. of allergen groupsa
 0 NA 28 (26.7) 9 (8.6) .10
 1 NA 10 (9.5) 4 (3.8)
 2 NA 11 (10.5) 1 (0.9)
 3–5 NA 12 (11.4) 11 (10.5)
 >5 NA 11 (10.5) 8 (7.6)
Abbreviation: NA, not applicable.
Boldface indicates significance.
aAn allergen group consisted of positive test results to at least one allergen grouped by categories: dust mites, cat, dog, cockroach, molds, trees, 
grasses, and/or weeds.
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Table 3
Response Status to Management and by Age Group
Management type No. (%) of patients P value
Complete responders (n = 72) Nonresponders (n = 33)
Management type
 None 1 (1.4) 0 (0.0) .03
 Diet elimination 32 (44.4) 19 (57.6)
 Swallowed corticosteroids 21 (29.2) 2 (6.1)
 Diet elimination and corticosteroids 18 (25.0) 12 (36.3)
Diet elimination (alone or with swallowed corticosteroids)
 Allergen specific elimination 39 (54.2) 29 (87.9) .90
 6-Food elimination 11 (15.3) 10 (30.3)
 Elemental 1 (1.4) 1 (3.0)
Age, y
 5 (n = 52) 32 (61.5) 12 (36.4) .049
 6e11 (n = 42) 28 (66.6) 8 (24.2)
 12 (n = 29) 12 (41.3) 13 (39.4)
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Table 4
Association of Perennial Allergen Sensitization, Age, and Response Status
Age Group and perennial allergen testing result No. (%) of tested patients P value
Complete responders Nonresponders
<5 years (n = 44)
 Positive 15 (46.9) 6 (50) .99
 Negative 17 (53.1) 6 (50)
6–11 years (n = 36)
 Positive 10 (35.7) 7 (87.5) .02
 Negative 18 (64.3) 1 (12.5)
>12 years (n = 25)
 Positive 8 (66.7) 11 (84.6) .38
 Negative 4 (33.3) 2 (15.4)
Boldface indicates significance.
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Table 5
Associated Between Cockroach and Mold Sensitization and Response Status
Result Cockroach Mold
Complete responders Nonresponders P value Complete responders Nonresponders P value
Total
 Positive 6 (8.6) 8 (24.2) .06 16 (22.5) 14 (42.4) .06
 Negative 64 (91.4) 25 (75.8) 55 (77.5) 19 (57.6)
Diet restriction
 Positive 4 (12.9) 1 (5.3) .64 9 (28.1) 6 (31.6) >.99
 Negative 27 (87.1) 18 (94.7) 23 (71.9) 13 (68.4)
Swallowed corticosteroids
 Positive 2 (10.0) 1 (50.0) .26 3 (15.0) 0 (0) >.99
 Negative 18 (90.0) 1 (50.0) 17 (85.0) 2 (100)
Diet and corticosteroids
 Positive 0 (0) 6 (50.0) .002 4 (22.2) 8 (66.7) .02
 Negative 18 (100) 6 (50.0) 14 (77.8) 4 (33.3)
Boldface indicates significance.
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